Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies.\nTheir lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas.\nThey intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Exostemtech Co., Ltd. is a company headquartered in Ansan-si, the South Korea. The firm operates as medical care company, which develops cell-free therapeutic systems. It was founded in 2016 by Yong-Woo Cho, he has been the CEO since then.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ichimaru Pharcos Co. Ltd. is a Japanese private company. The firm specializes in research and development, manufacturing and selling of raw materials for cosmetics, health foods and quasi drugs.

XOMA Technology Ltd., a subsidiary of XOMA Corp., is a company headquartered in Bermuda focused on pharmaceutical preparations.

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Zhejiang Zhuoyun Biotechnology Co., Ltd., established on 2014-03-03, The business scope includes technical research and development of biological enzymes and reagents;second,Three categories6840Manufacture of in vitro diagnostic reagents,processing(Operate within the validity period of the license);Medical Biotechnology Consulting,transfer;Maintenance of Class I Medical Devices;Washing fluid,Wholesale of chemical reagents;Bioresearch Reagents,Research and development of bioengineering materials and equipment,wholesale,retail;Self-operated or agent import and export of goods and technologies,Except for goods and technologies that are restricted or prohibited from being imported or exported by the state;second,Wholesale of three types of medical devices and accessories,retail;Class III in vitro diagnostic reagents(Does not contain drugs)Wholesale,retail;second,Leasing of three types of clinical laboratory analysis instruments and other legally,regulations,Projects that are not prohibited or do not require operating permits and projects that are not included in the negative list of local industrial development in the decision of the State Council.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Lanzhou Yahua Biotechnology Co., Ltd., established on 2001-04-17, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)*** General project:Medical Research and Experimental Development.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)***

Reigncom has technology innovation projects and production, learning, and research projects funded by STCSM, STCMD, and funds and is engaged in the research, development, manufacturing, and distribution of diagnostic medical devices, IVD reagent kits, and related services.

Shenzhen Hongmei Diagnostic Technology Co., Ltd., established on 2015-10-10, Business scope includes general business items:Technology development of biomedical diagnostic products,technical consulting,and the transfer of self-owned technological achievements;Instrumentation,computer,Software and Auxiliary Equipment,Sales of machinery and equipment;Import and export related supporting business(involved in state trade,quota,Commodities stipulated in licenses and special management,According to the relevant regulations of the state to apply for operation)(None of the above projects involve special management measures for foreign investment access),The licensing program is:Class II medical device(In vitro diagnostic reagents)wholesale and retail;Class II22Clinical laboratory equipment-14Production of culture and incubation equipment,Class II6840Clinical Laboratory Analytical Instruments,Class II6840In vitro diagnostic reagents#production.(None of the above projects involve special management measures for foreign investment access)

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Shenzhen Jinzhun Biomedical Engineering Co., Ltd., established on 2014-03-07, Business scope includes general business items:equipment,medical equipment,diagnostic instrument,Diagnostic reagents,software,Consumables,Research and development of biological products;Chemical Products(Free of Hazardous Chemicals)promotion of;Import and export of goods and technology;Invest in business(Specific projects will be reported separately);Domestic Trade.,The licensing program is:equipment,medical equipment,diagnostic instrument,Diagnostic reagents,software,Consumables,Production and sales of biological products.